Standard BioTools (NASDAQ:LAB) shareholders have endured a 76% loss from investing in the stock five years ago [Yahoo! Finance]
Standard BioTools Inc. (LAB)
Company Research
Source: Yahoo! Finance
Anyone who held Standard BioTools Inc. NASDAQ:LAB ) for five years would be nursing their metaphorical wounds since the share price dropped 76% in that time. Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Because Standard BioTools made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. Over five years, Standard BioTools grew its revenue at 2.6% per year. That's far from impressive given all the mone
Show less
Read more
Impact Snapshot
Event Time:
LAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LAB alerts
High impacting Standard BioTools Inc. news events
Weekly update
A roundup of the hottest topics
LAB
News
- Standard BioTools Completes Sale of SomaLogic to IlluminaGlobeNewswire
- Standard BioTools (NASDAQ:LAB) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team [Yahoo! Finance]Yahoo! Finance
- Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 RevenueGlobeNewswire
- Standard BioTools: Outlook Still Murky [Seeking Alpha]Seeking Alpha
LAB
Earnings
- 8/11/25 - Miss
LAB
Sec Filings
- 1/30/26 - Form 8-K
- 1/8/26 - Form 8-K
- 1/7/26 - Form SCHEDULE
- LAB's page on the SEC website